Instructor, Dr. Julie Bridge’s research laboratory
Tumor Molecular Cytogenetics and Molecular Genetics, Tissue Banking Core Facility, Breast Cancer Collaborative Registry (BCCR)
Education and Training
M.D., Fujian Medical University, Fujian, P.R. China, 1992
Pathology Residency, Fujian Medical University 1st Affiliated University Hospital, P.R. China, 1997
Post-doctoral training, University of Nebraska Medical Center, 1998-2000
Member, American Society of Human Genetics (1999-2001)
Member, Society for Basic Urologic Research (2004)
Member, American Association for Cancer Research (2004-2007)
Postdocs and Research Laboratory Technologists
Cytology Technologist Students – FISH lecture
Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M, Bridge JA. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol. 2010 Nov 12.
Huang D, Sumegi J, Dal Cin P, Reith JD, Yasuda T, Nelson M, Muirhead D, Bridge JA. C11orf95-MKL2 is the resulting fusion oncogene of t(11;16)(q13;p13) in chondroid lipoma. Genes Chromosomes Cancer. 2010 Sep;49(9):810-8.
Richardson T, McCanse W, Casale GP, Huang D, Tian J, Elkahwaji JE, Lele S, Hemstreet GP. Tissue-based quantification of 8-hydroxy-2'-deoxyguanosine in human prostate biopsies using quantitative fluorescence imaging analysis. Urology. 2009 Nov;74(5):1174-9.
Huang D, Casale GP, Tian J, Lele SM, Pisarev VM, Simpson MA, Hemstreet GP 3rd. Udp-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer. Int J Cancer. 2010 Jan 15;126(2):315-27.
Huang D, Casale GP, Tian J, Wehbi NK, Abrahams NA, Kaleem Z, Smith LM, Johansson SL, Elkahwaji JE, Hemstreet GP 3rd. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to beta-catenin in archived prostate specimens. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1371-81.
Beiraghi S, Zhou M, Talmadge CB, Went-Sumegi N, Davis JR, Huang D, Saal H, Seemayer TA, Sumegi J. Identification and characterization of a novel gene disrupted by a pericentric inversion inv(4)(p13.1q21.1) in a family with cleft lip. Gene. 2003 Apr 24;309(1):11-21.
Huang D, Eudy JD, Uzvolgyi E, Davis JR, Talmadge CB, Pretto D, Weston MD, Lehman JE, Zhou M, Seemayer TA, Ahmad I, Kimberling WJ, Sumegi J. Identification of the mouse and rat orthologs of the gene mutated in Usher syndrome type IIA and the cellular source of USH2A mRNA in retina, a target tissue of the disease. Genomics. 2002 Aug;80(2):195-203.
Sumegi J, Seemayer TA, Huang D, Davis JR, Morra M, Gross TG, Yin L, Romco G, Klein E, Terhorst C, Lanyi A. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma. 2002 Jun;43(6):1189-201. Review.
Fields RR, Zhou G, Huang D, Davis JR, Möller C, Jacobson SG, Kimberling WJ, Sumegi J. Usher syndrome type III: revised genomic structure of the USH3 gene and identification of novel mutations. Am J Hum Genet. 2002 Sep;71(3):607-17.
Janos Sumegi, Dali Huang, Arpad Lanyi, Jack D. Davis, Thomas A. Seemayer, Akihiko Maeda, George Klein, Marco Serri, Hiroshi Wakiguchi, David T. Purtilo, Thomas G. Gross. Correlation of Mutations of the SH2D1A gene and Epstein-Barr virus (EBV) infection with Clinical Phenotype and Outcome in X-linked lymphoproliferative disease (XLP). BLOOD, Journal of the American society of hematology. 2000;96(9):3118-3125.
For a detailed list of publications, click here.
985900 Nebraska Medical Center
Omaha, Ne 68198-5900
DRC 2 6042